Publication | Closed Access

First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study

Metastatic Breast CancerOncologyBreast OncologyMedicineBreast CancerPharmacotherapyIii StudyCancer TreatmentPharmacologyGynecology OncologyPostmenopausal Women